Navigation Links
Omeros Adds Four More Unlocked Orphan GPCRs to its Portfolio
Date:5/3/2012

nts undergoing a wide range of surgical and medical procedures. Omeros has four ongoing clinical development programs. Omeros may also have the near-term capability, through its GPCR program, to add a large number of new drug targets and their corresponding compounds to the market. Behind its clinical candidates and GPCR platform, Omeros is building a diverse pipeline of protein and small-molecule preclinical programs targeting inflammation, coagulopathies and central nervous system disorders.

Forward-Looking Statements

This press release contains forward-looking statements as defined within the Private Securities Litigation Reform Act of 1995, which are subject to the "safe harbor" created by those sections. These statements include, but are not limited to, the number of orphan GPCRs that Omeros expects to unlock; the potential indications of the orphans GPCRs unlocked by Omeros; Omeros' patent objective for each unlocked orphan GPCR; and that Omeros may have capability, through its GPCR program, to add a large number of new drug targets and their corresponding compounds to the market. Forward-looking statements are based on management's beliefs and assumptions and on information available to management only as of the date of this press release. Omeros' actual results could differ materially from those anticipated in these forward-looking statements for many reasons, including, without limitation, the risks, uncertainties and other factors described under the heading "Risk Factors" in the Company's Annual Report on Form 10-K filed with the Securities and Exchange Commission on March 15, 2012. Given these risks, uncertainties and other factors, you should not place undue reliance on these forward-looking statements, and the Company assumes no obligation to update these forward-looking statements publicly, even if new information becomes available in the future.

 


'/>"/>
SOURCE Omeros Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Omeros Announces Initiation of Patient Enrollment in OMS201 Phase 1 Study
2. Omeros Announces Publication of Clinical Results for OMS103HP in Arthroscopy: The Journal of Arthroscopic and Related Surgery
3. Omeros Announces Patient Enrollment in Phase 1/Phase 2 Study of OMS302
4. Omeros and The Parkinsons Institute and Clinical Center Enter into a Collaboration Agreement to Evaluate Novel Target for the Treatment of Movement Disorders
5. Omeros Receives $3.1 Million Milestone Payment from The Stanley Medical Research Institute for Schizophrenia Program
6. Omeros Prices Initial Public Offering of Common Stock at $10.00 Per Share
7. Omeros Announces National Institute on Drug Abuses Support for Phase 2 Clinical Study in Addiction Program
8. Omeros Corporation to Host Third Quarter 2009 Financial Results Conference Call on November 19
9. Daniel K. Spiegelman Elected to Board of Directors of Omeros
10. Omeros Reports Additional Phase 2 Data Showing Multiple Clinical Benefits In Patients Undergoing Meniscectomy Surgery
11. Omeros Selects Clinical Candidate for MASP-2 Program With Potential Applicability to Multiple Inflammatory Disorders
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/28/2015)... FORT WORTH, Texas , July 28, 2015 /PRNewswire/ ... Report "Global Dermatology Devices Market by Type (Dermatology Treatment ... MRI, CT), Dermatoscopes, Microscopes]), by Application, by Geography - ... market is expected to reach $11.88 billion by 2019, ... Browse through the TOC of Global Dermatology ...
(Date:7/28/2015)... , July 28, 2015 Research ... addition of the "Global Hearing Aids Market ... The global hearing aids market to grow ... 2014-2019. Factors such as changing ... driving market growth. The market has witnessed immense ...
(Date:7/28/2015)... 2015   CSL Behring announced today ... Authorization Application (MAA) for the company,s investigational long-acting ... recombinant albumin (rIX-FP) for the prophylaxis and treatment ... Upon Swissmedic approval, rIX-FP will provide hemophilia B ... intervals up to 14 days. ...
Breaking Medicine Technology:Global Dermatology Devices Market to be Worth $11.88 Billion by 2019 2Global Dermatology Devices Market to be Worth $11.88 Billion by 2019 3Global Hearing Aids Market 2015-2019 with G N Store Nord, Sonova Holdings & William Demant Dominating 2Swissmedic Accepts for Review CSL Behring's MAA for rIX-FP for Patients with Hemophilia B 2Swissmedic Accepts for Review CSL Behring's MAA for rIX-FP for Patients with Hemophilia B 3Swissmedic Accepts for Review CSL Behring's MAA for rIX-FP for Patients with Hemophilia B 4
... Phosphagenics,Limited (ASX: POH, AIM: PSG, OTCQX: PPGNY) today ... undertake a Phase 1 transdermal,oxycodone clinical trial aimed ... management product. Phosphagenics has submitted all necessary ... be conducted at CMAX - an independent clinical ...
... Phase 2 clinical development, PRINCETON, N.J., Sept. ... in the discovery and development of novel,small molecule ... 2a,clinical study of PS433540, the company,s lead internal ... receptor antagonist,(DARA) that is being developed as a ...
Cached Medicine Technology:Phosphagenics to Conduct a Phase 1 Transdermal Oxycodone Clinical Trial 2Pharmacopeia Initiates Phase 2 Hypertension Study with PS433540 (DARA) 2Pharmacopeia Initiates Phase 2 Hypertension Study with PS433540 (DARA) 3Pharmacopeia Initiates Phase 2 Hypertension Study with PS433540 (DARA) 4Pharmacopeia Initiates Phase 2 Hypertension Study with PS433540 (DARA) 5
(Date:7/28/2015)... ... July 28, 2015 , ... ... that Schneider Electric has completed its upgrade and expansion of its ... with more than 170,000 employees in 134 countries supplying a wide range of ...
(Date:7/28/2015)... , ... July 28, 2015 , ... ... of Directors has authorized the Company, from time to time and depending on ... value of up to $25 million. Repurchases will be made in open market ...
(Date:7/28/2015)... ... July 28, 2015 , ... Women fear developing Alzheimer's disease ... that cancer, heart attack, and stroke are treatable, but there is little an individual ... is to take part in a clinical trial, reports the July 2015 Harvard ...
(Date:7/28/2015)... ... July 28, 2015 , ... A new study published by ... Study Says " sheds light on a possible new treatment option for people living ... of regular HBOT sessions, at least five per week, patients experienced a significant decrease ...
(Date:7/28/2015)... ... ... Most employers have been using multi-tier prescription drug plans for many years, but ... in the use of 4-tier plans, which typically cover the highest cost drugs, as ... to continue, according to UBA. , UBA’s survey finds that, since 2009, the number ...
Breaking Medicine News(10 mins):Health News:Schneider Electric Amps Up Its Use of Kinetic Data’s Enterprise Request Management Software 2Health News:Schneider Electric Amps Up Its Use of Kinetic Data’s Enterprise Request Management Software 3Health News:Schneider Electric Amps Up Its Use of Kinetic Data’s Enterprise Request Management Software 4Health News:Safeguard Scientifics Board of Directors Authorizes up to $25 Million Share Repurchase Program 2Health News:Safeguard Scientifics Board of Directors Authorizes up to $25 Million Share Repurchase Program 3Health News:Fight Alzheimer's By Taking Part in a Clinical Trial, From the July 2015 Harvard Women's Health Watch 2Health News:Fight Alzheimer's By Taking Part in a Clinical Trial, From the July 2015 Harvard Women's Health Watch 3Health News:Recovery Specialists Discuss How Oxygen Therapy Can Ease Fibromyalgia 2Health News:Recovery Specialists Discuss How Oxygen Therapy Can Ease Fibromyalgia 3Health News:Employers Use of Multi-Tier Pharmacy Benefits Continues to Rise 2Health News:Employers Use of Multi-Tier Pharmacy Benefits Continues to Rise 3Health News:Employers Use of Multi-Tier Pharmacy Benefits Continues to Rise 4Health News:Employers Use of Multi-Tier Pharmacy Benefits Continues to Rise 5
... LOS ANGELES, May 29 Writers and producers,from ... others were honored,at the 2008 Voice Awards last ... Administration (SAMHSA), hosted by award-winning actor and,mental health ... at Paramount Studios in Los Angeles., Winners ...
... ALOKA announced today new compact,ProSound ultrasound Systems which ... Federation of Societies for Ultrasound in Medicine and ... in Timisoara, Romania. The ProSound 2 is a,portable ... functions. High image quality technologies developed for,the premium ...
... The gene that allows fireflies to flash is helping ... UT Southwestern Medical Center researchers are among the first to ... used to determine the effectiveness of cancer drugs that choke ... requires a substrate called luciferin to be added to the ...
... More northern women feel bloating and,gurgling than their southern ... it at any one time, according to a TNS ... and Yorkshire and Humberside fared the,worst (71%), with Greater ... bloated feelings. And 61% of British women experience feeling,bloated, ...
... receiving the necessary symptom management that they require to ... its treatment, or both, according to a leading professor ... million people around the world (10 million in the ... newly diagnosed with cancer can expect to live at ...
... July 10 Cash Dividend ... - Preliminary Proxy Results, WALNUT CREEK, Calif., May 28 ... and the,preliminary proxy results at its 2008 Annual Meeting of Stockholders., ... dividend on common shares of $0.14 per share payable July,10, 2008 to ...
Cached Medicine News:Health News:SAMHSA Honors 'The Sopranos,' 'Monk,' 'Dirt' at Star-Studded Voice Awards in Los Angeles 2Health News:SAMHSA Honors 'The Sopranos,' 'Monk,' 'Dirt' at Star-Studded Voice Awards in Los Angeles 3Health News:SAMHSA Honors 'The Sopranos,' 'Monk,' 'Dirt' at Star-Studded Voice Awards in Los Angeles 4Health News:ALOKA to Unveil a New Compact 'ProSound' Diagnostic Ultrasound System 2Health News:Fireflies' glow helps UT Southwestern researchers track cancer drug's effectiveness 2Health News:Fireflies' glow helps UT Southwestern researchers track cancer drug's effectiveness 3Health News:North South Divide Exists in UK Digestive Health 2Health News:North South Divide Exists in UK Digestive Health 3Health News:Cancer survivors are living 'in limbo' with unmet needs for care 2Health News:Cancer survivors are living 'in limbo' with unmet needs for care 3Health News:Longs Drug Stores Corporation Announced at Its Annual Meeting of Stockholders 2
... Intelli-Storeroom™ was developed to create physically secured ... and exits are converted to RFID portals. ... readers and antennas by VerdaSee's Field Engineering ... to assets that are to be tracked. ...
... Mobile Aspects provides hospitals ... products to track all their ... Our RFID systems remove all ... items and people accurately. iRIS, ...
The WatchMate LC model is a cost-effective solution for monitoring a single exit, and provides local notification of an alarm....
... AgileTrac Surgical Services is a Web-based ... to track, manage, and measure patient flow ... process, from admission to discharge. AgileTrac collects ... of care delays your patient might experience. ...
Medicine Products: